The fact that the SOCE inhibitor BTP2 suppressed the TLR4 signaling in breast cancer cells, whereas the SOCE activator Thapsigargin enhanced this signaling pathway further, suggested that the effect observed on the TLR4 signaling was mainly due to their actions on SOCE, rather than any unique non-specific actions of either drug. Here, TLR4 is linked to breast carcinoma.